<?xml version='1.0' encoding='utf-8'?>
<document id="29311093"><sentence text="Characterization of the Preclinical Pharmacology of the New 2-Aminomethylphenol, JPC-3210, for Malaria Treatment and Prevention."><entity charOffset="60-79" id="DDI-PubMed.29311093.s1.e0" text="2-Aminomethylphenol" /><entity charOffset="81-89" id="DDI-PubMed.29311093.s1.e1" text="JPC-3210" /><pair ddi="false" e1="DDI-PubMed.29311093.s1.e0" e2="DDI-PubMed.29311093.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29311093.s1.e0" e2="DDI-PubMed.29311093.s1.e1" /></sentence><sentence text="The new 2-aminomethylphenol, JPC-3210, has potent in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, low cytotoxicity, and high in vivo efficacy against murine malaria"><entity charOffset="8-27" id="DDI-PubMed.29311093.s2.e0" text="2-aminomethylphenol" /><entity charOffset="29-37" id="DDI-PubMed.29311093.s2.e1" text="JPC-3210" /><pair ddi="false" e1="DDI-PubMed.29311093.s2.e0" e2="DDI-PubMed.29311093.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29311093.s2.e0" e2="DDI-PubMed.29311093.s2.e1" /></sentence><sentence text=" Here we report on the pharmacokinetics of JPC-3210 in mice and monkeys and the results of in vitro screening assays, including the inhibition of cytochrome P450 (CYP450) isozymes" /><sentence text=" In mice, JPC-3210 was rapidly absorbed and had an extensive tissue distribution, with a brain tissue-to-plasma concentration ratio of about 5" /><sentence text="4" /><sentence text=" JPC-3210 had a lengthy plasma elimination half-life of about 4" /><sentence text="5 days in mice and 11" /><sentence text="8 days in monkeys" /><sentence text=" JPC-3210 exhibited linear single-oral-dose pharmacokinetics across the dose range of 5 to 40 mg/kg of body weight with high oral bioavailability (âˆ¼86%) in mice" /><sentence text=" Systemic blood exposure of JPC-3210 was 16" /><sentence text="6% higher in P" /><sentence text=" berghei-infected mice than in healthy mice" /><sentence text=" In vitro studies with mice and human hepatocytes revealed little metabolism and the high metabolic stability of JPC-3210" /><sentence text=" The abundance of human metabolites from oxidation and glucuronidation was 2" /><sentence text="0% and 2" /><sentence text="5%, respectively" /><sentence text=" CYP450 studies in human liver microsomes showed JPC-3210 to be an inhibitor of CYP2D6 and, to a lesser extent, CYP3A4 isozymes, suggesting the possibility of a metabolic drug-drug interaction with drugs that are metabolized by these isozymes" /><sentence text=" In vitro studies showed that JPC-3210 is highly protein bound to human plasma (97%)" /><sentence text=" These desirable pharmacological findings of a lengthy blood elimination half-life, high oral bioavailability, and low metabolism as well as high in vivo potency have led the Medicines for Malaria Venture to select JPC-3210 (MMV892646) for further advanced preclinical development" /><sentence text="" /></document>